Jiangsu Hengrui Pharmaceuticals (600276.SH) signed an exclusive license agreement for the SHR6508 project with HANSOH PHARMA.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has signed an exclusive licensing agreement with HANSOH PHARMA Group Limited ("HANSOH PHARMA") to license the company's SHR6508 project to HANSOH PHARMA for a fee; the company's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. ("Chengdu Shengdi") has signed a Commercialization Service Framework Agreement with HANSOH PHARMA's subsidiary Jiangsu Haosen Pharmaceutical Group Co., Ltd. ("Haosen Pharmaceutical"), entrusting Haosen Pharmaceutical to provide non-exclusive commercialization services for the company's paricalcitol soft capsules product. According to the announcement, SHR6508 is a novel calcium-sensing receptor modulator intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who require hemodialysis. It is currently undergoing Phase III clinical trial research. The calcium-sensing receptor monitors and regulates calcium levels by releasing parathyroid hormone (PTH). Due to increased sensitivity to calcium ions, SHR6508 administration can reduce PTH secretion in hemodialysis patients with secondary hyperparathyroidism. Paricalcitol is a synthetic analog of vitamin D that inhibits the secretion of parathyroid hormone (PTH) by binding to the vitamin D receptor, thereby lowering serum PTH levels. The company's paricalcitol soft capsules were approved by the National Medical Products Administration in November 2025. The announcement reveals that HANSOH PHARMA and Haosen Pharmaceutical are controlled by Mr. Sun Piaoyang, the actual controller and chairman of the company, in accordance with listing rules, making them related parties of the company. HANSOH PHARMA is a leading innovative pharmaceutical company in China, with subsidiaries such as Haosen Pharmaceutical, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases.